Navigation Links
Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
Date:12/20/2007

SOUTH SAN FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire- FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology, commonly referred to as lentiviral vectors. Pursuant to the agreement, Cell Genesys has received a payment of $12 million from GBP IP, LLC in exchange for all intellectual property and previously established licensing agreements relating to its lentiviral gene delivery technology. Cell Genesys will retain rights to use the technology for research and development purposes, including potential future use with cancer immunotherapy products.

"We are pleased to have entered into this agreement with GBP IP, LLC and Lentigen, a leader in the field of lentiviral gene delivery technology, and wish them every success in the further development of this important technology," stated Robert Tidwell, senior vice president of corporate development at Cell Genesys. "This agreement reflects Cell Genesys' ongoing commitment and ability to leverage its non-core business assets and in so doing build shareholder value."

Over the years, Cell Genesys has successfully leveraged its non-core business assets through strategic spin outs and outlicensing agreements. In 1996, Cell Genesys spun out its antibody technology creating Abgenix, a company that was acquired in 2005 by Amgen for approximately $2.6 billion. In 2001, Cell Genesys launched Ceregene, a privately held company that is focused on developing gene therapies for neurodegenerative disorders. Cell Genesys currently holds a
'/>"/>

SOURCE Cell Genesys, Inc.; GBP IP, LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... to rule the world, the honey bee, Apis mellifera, ... demonstrates that when these honey bees arrive in a ... from the genetic endowment of their predecessors. , ... in Proceedings of the National Academy of Sciences. , ...
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the ... press conference on Monday, March 3, 2008, at,12:30 p.m. ... be held this year in New Orleans., Marc ... provide an overview of the company, and Dr. Ian ...
... $160 million or more, up from $42 ... - First HGS product sales expected with delivery of ABthrax(TM) to ... - First Albuferon(R) Phase 3 data expected late 2008 -, - Enrollment completed ... ...
Cached Biology Technology:Honey bee invaders exploit the genetic resources of their predecessors 2Honey bee invaders exploit the genetic resources of their predecessors 3Thermo Fisher Scientific to Webcast Press Conference at PITTCON 2008 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 4Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 5Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 6Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 7Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 8Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 9Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 10Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 11
(Date:12/19/2014)... LaunchKey , the first decentralized mobile authentication and authorization ... era, today announced the close of $3 million in ... Metamorphic Ventures with participation from ENIAC Ventures, Crosslink Capital, ... has raised $4 million to date, and will use ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming in ... in biomedical applications. Chemical sensors help in recording of ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Ore. Wildfire, insect outbreaks and hurricanes destroy huge ... of carbon dioxide entering the atmosphere, but scientists are ... affect their climate impact. Researchers conclude in a ... amount of energy reflected back into space, is important ...
... Researchers at Case Western Reserve University School of Medicine ... to two weeks after donor death work as well as ... National Eye Institute has awarded a $12.3 million grant to ... nationwide meets current needs about 40,000 transplants in 2010. ...
... (Boston) The National Institutes of Health (NIH) ... and the College of Engineering (COE) a five ... Caroline Genco, PhD, research director, Section of Infectious ... is the principal investigator alongside Selim nl, PhD, ...
Cached Biology News:'Albedo effect' in forest disturbances can cause added warming, bonus cooling 2'Albedo effect' in forest disturbances can cause added warming, bonus cooling 3Study seeks to widen corneal transplant window 2Study seeks to widen corneal transplant window 3NIH training grant awarded to Boston University School of Medicine and College of Engineering 2
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
...
...
... isomers are predominantly used for labeling proteins, ... labeling peptides and nucleotides because they give ... often required in the conjugation processes. 5-TAMRA ... labeling peptides and proteins. 6-TAMRA is predominately ...
Biology Products: